Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AMNEAL PHARMACEUTICALS, INC. (AMRX) vs Dr. Reddy's Laboratories Ltd (RDY)

AMNEAL PHARMACEUTICALS, INC. and Dr. Reddy's Laboratories Ltd are both Drug Manufacturers Specialty & Generic companies. Dr. Reddy's Laboratories Ltd is the larger, with a market value of $10.0B against $6.3B — 1.6× the size. Dr. Reddy's Laboratories Ltd trades at the lower P/E: 30.8× against 39.5×. AMNEAL PHARMACEUTICALS, INC. grew revenue faster over the last twelve months: 9.28% against −11.6%. Dr. Reddy's Laboratories Ltd has the higher net margin (9.81% vs 5.05%) and the lower return on invested capital (5.89% vs 11.1%). Both pay a dividend; Dr. Reddy's Laboratories Ltd yields more (0.66% vs 0.27%). Across the 22 metrics below, Dr. Reddy's Laboratories Ltd leads on 14 and AMNEAL PHARMACEUTICALS, INC. on 8.

Valuation

Metric AMRX RDY Drug Manufacturers Specialty & Generic median
P/E 39.54 30.85 20.14
P/S 2.02 2.79 2.25
P/B 191.09 2.35 1.90
Price to free cash flow n/m 69.03 16.54
EV/EBITDA 13.30 15.92 12.29
EV/Sales 2.84 2.76 2.56
Earnings yield 2.53% 3.24% (2.99%)
Free cash flow yield (0.18%) 1.45% 0.00%

Profitability

Metric AMRX RDY Drug Manufacturers Specialty & Generic median
Gross margin 39.32% 50.00% 53.94%
Operating margin 14.56% 10.91% 0.00%
Net margin 5.05% 9.81% 0.00%
Free cash flow margin (0.37%) 4.05% 0.00%
Return on equity (395.84%) 8.21% (0.40%)
Return on assets 4.37% 5.55% (3.32%)
Return on invested capital 11.05% 5.89% 0.00%

Growth

Metric AMRX RDY Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 9.28% (11.60%) 10.01%
EPS growth (last fiscal year) 157.89% (30.38%) —
Revenue growth, 5-year CAGR 8.66% 6.66% 6.74%
Net income growth, 5-year CAGR (4.57%) 14.08% 0.00%

Health

Metric AMRX RDY Drug Manufacturers Specialty & Generic median
Debt to equity 80.86 0.19 0.05
Current ratio 2.20 1.90 2.31
Net debt to EBITDA 3.62 (0.15) 0.85

Dividend

Metric AMRX RDY Drug Manufacturers Specialty & Generic median
Dividend yield 0.27% 0.66% 1.70%
Payout ratio 0.00 0.14 0.00

Size

Metric AMRX RDY Drug Manufacturers Specialty & Generic median
Market cap 6.32b 10.02b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack